RS64821B1 - Režim doziranja anti-ifnar1 za subkutane injekcije - Google Patents

Režim doziranja anti-ifnar1 za subkutane injekcije

Info

Publication number
RS64821B1
RS64821B1 RS20230991A RSP20230991A RS64821B1 RS 64821 B1 RS64821 B1 RS 64821B1 RS 20230991 A RS20230991 A RS 20230991A RS P20230991 A RSP20230991 A RS P20230991A RS 64821 B1 RS64821 B1 RS 64821B1
Authority
RS
Serbia
Prior art keywords
ifnar1
subcutaneous injection
dosing regime
regime
dosing
Prior art date
Application number
RS20230991A
Other languages
English (en)
Inventor
Catharina Lindholm
Yen Lin Chia
Rajendra Tummala
Lorin Roskos
Joachim Almquist
Tomas Rouse
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of RS64821B1 publication Critical patent/RS64821B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Devices For Medical Bathing And Washing (AREA)
RS20230991A 2021-04-23 2022-04-21 Režim doziranja anti-ifnar1 za subkutane injekcije RS64821B1 (sr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163178739P 2021-04-23 2021-04-23
US202163245285P 2021-09-17 2021-09-17
US202163272851P 2021-10-28 2021-10-28
PCT/EP2022/060592 WO2022223714A1 (en) 2021-04-23 2022-04-21 Anti-ifnar1 dosing regime for subcutaneous injection
EP22724683.2A EP4114465B1 (en) 2021-04-23 2022-04-21 Anti-ifnar1 dosing regime for subcutaneous injection

Publications (1)

Publication Number Publication Date
RS64821B1 true RS64821B1 (sr) 2023-12-29

Family

ID=81750490

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20230991A RS64821B1 (sr) 2021-04-23 2022-04-21 Režim doziranja anti-ifnar1 za subkutane injekcije

Country Status (23)

Country Link
US (2) US20220340669A1 (sr)
EP (2) EP4114465B1 (sr)
JP (1) JP7484027B2 (sr)
KR (1) KR20230166134A (sr)
AU (2) AU2022260531B2 (sr)
BR (1) BR112023021761A2 (sr)
CA (1) CA3216387A1 (sr)
CL (1) CL2023003114A1 (sr)
CO (1) CO2023015498A2 (sr)
DK (1) DK4114465T5 (sr)
ES (1) ES2963757T3 (sr)
FI (1) FI4114465T3 (sr)
HR (1) HRP20231255T1 (sr)
HU (1) HUE063562T2 (sr)
IL (1) IL307748A (sr)
LT (1) LT4114465T (sr)
MX (1) MX2023012465A (sr)
PL (1) PL4114465T3 (sr)
PT (1) PT4114465T (sr)
RS (1) RS64821B1 (sr)
SI (1) SI4114465T1 (sr)
TW (1) TW202317182A (sr)
WO (1) WO2022223714A1 (sr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113621063A (zh) * 2021-08-02 2021-11-09 江苏荃信生物医药有限公司 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004299833B2 (en) 2003-12-10 2009-05-07 E. R. Squibb & Sons, L.L.C. Interferon alpha antibodies and their uses
EP2662390B1 (en) * 2004-06-21 2017-08-02 E. R. Squibb & Sons, L.L.C. Interferon alpha receptor 1 antibodies and their uses
EP2666874B1 (en) 2007-07-12 2015-05-27 The Brigham and Women's Hospital, Inc. Compositions and methods for diagnosing and assessing inflammatory myopathies
KR101666229B1 (ko) 2008-02-08 2016-10-14 메디뮨 엘엘씨 Ｆｃ 리간드 친화성이 감소된 항-ＩＦＮＡＲ１ 항체
KR20120101340A (ko) 2009-09-03 2012-09-13 메디뮨 엘엘씨 1형 인터페론 진단
CN108310375A (zh) 2012-06-13 2018-07-24 米迪缪尼有限公司 针对抗i型干扰素受体（ifnar）抗体的固定剂量方案
WO2017031288A1 (en) 2015-08-19 2017-02-23 Medimmune, Llc Stable anti-ifnar1 formulation
CN106243226B (zh) 2016-08-05 2019-02-12 北京智仁美博生物科技有限公司 抗人ifnar1的抗体及其用途
MX2021003146A (es) * 2018-09-18 2021-06-23 I Mab Biopharma Hangzhou Co Ltd Anticuerpos anti-ifnar1 para tratar enfermedades autoinmunitarias.
JP7522749B2 (ja) 2019-02-15 2024-07-25 アストラゼネカ・アクチエボラーグ Ｉ型インターフェロン媒介性障害
TW202237647A (zh) * 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
IL302871A (en) * 2020-11-18 2023-07-01 Astrazeneca Ab Saving steroids
CN113278070B (zh) 2021-04-25 2022-06-14 福州迈新生物技术开发有限公司 抗ck17蛋白单克隆抗体及其细胞株、制备方法和应用
CN113521276B (zh) * 2021-07-13 2022-04-12 江苏荃信生物医药股份有限公司 包含抗人干扰素α受体1(IFNAR1)单克隆抗体的液体制剂

Also Published As

Publication number Publication date
FI4114465T3 (fi) 2023-10-31
HRP20231255T1 (hr) 2024-02-02
LT4114465T (lt) 2023-11-10
EP4306541A3 (en) 2024-03-27
ES2963757T3 (es) 2024-04-01
AU2022260531A9 (en) 2023-12-07
AU2024201743A1 (en) 2024-04-04
AU2022260531A1 (en) 2023-11-30
EP4306541A2 (en) 2024-01-17
DK4114465T3 (da) 2023-10-30
EP4114465B1 (en) 2023-08-30
EP4114465A1 (en) 2023-01-11
KR20230166134A (ko) 2023-12-06
TW202317182A (zh) 2023-05-01
CO2023015498A2 (es) 2023-11-30
IL307748A (en) 2023-12-01
HUE063562T2 (hu) 2024-01-28
JP2024511227A (ja) 2024-03-12
US20230365698A1 (en) 2023-11-16
US20220340669A1 (en) 2022-10-27
CA3216387A1 (en) 2022-10-27
DK4114465T5 (da) 2024-07-22
AU2022260531B2 (en) 2024-03-07
SI4114465T1 (sl) 2023-11-30
WO2022223714A1 (en) 2022-10-27
JP7484027B2 (ja) 2024-05-15
PT4114465T (pt) 2023-11-03
CL2023003114A1 (es) 2024-04-19
PL4114465T3 (pl) 2024-04-08
BR112023021761A2 (pt) 2023-12-26
MX2023012465A (es) 2024-04-04

Similar Documents

Publication Publication Date Title
CA203536S (en) Injection device
CA206298S (en) Injection device
IL281712A (en) Injection systems for drug administration with internal power transmission
LT4114465T (lt) Anti-ifnar1 dozavimo režimas, skirtas poodinei injekcijai
GB2606984B (en) Injection device
GB202002075D0 (en) Improved injection device
SI3496926T1 (sl) Injektor za injekcijsko litje
GB2608691B (en) Drug Injection Device
CA200654S (en) Syringe injection gun
GB202318486D0 (en) Injection needle
GB2607940B (en) Injection administration device
GB2604353B (en) Improved Injector
GB2616906B (en) Injection device
GB202115495D0 (en) Injection device
GB202105845D0 (en) Injection device
ZA202003886B (en) Insulin injection pen
GB202101584D0 (en) Injection device
GB202101587D0 (en) Injection device
GB202006836D0 (en) Injection device
GB202006835D0 (en) Injection device
GB202215315D0 (en) Injection device